Lifecore Biomedical, Inc.
LFCRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 28, 2026 | Craig-Hallum | Matthew Hewitt | $6.28(-4%) | $6.52 | TheFly |
| Jun 16, 2026 | Barrington | $6.50(+18%) | $5.49 | TheFly | |
| Apr 29, 2026 | Barrington | $6.00(+17%) | $5.12 | TheFly | |
| Oct 4, 2024 | Stephens | Jacob Johnson | $5.00(-7%) | $5.38 | StreetInsider |
| Sep 5, 2024 | Craig-Hallum | Matthew Hewitt | $8.00(+90%) | $4.22 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Barrington Research | downgrade | Outperform →Market Perform | Sep 29, 2026 |
| William Blair | downgrade | Outperform →Market Perform | Sep 28, 2026 |
| Barrington Research | maintain | Outperform | Jun 16, 2026 |
| Barrington Research | maintain | Outperform | Apr 29, 2026 |
| Barrington Research | maintain | Outperform | Mar 27, 2026 |
| Barrington Research | maintain | Outperform | Mar 24, 2026 |
| Barrington Research | upgrade | Market Perform →Outperform | Mar 17, 2026 |
| Stephens & Co. | maintain | Equal Weight | Jan 3, 2025 |
| Craig-Hallum | maintain | Buy | Nov 22, 2024 |
| Barrington Research | downgrade | Outperform →Market Perform | Aug 28, 2024 |
| Stephens & Co. | maintain | Equal Weight | Sep 1, 2023 |
| Barrington Research | maintain | Outperform | Sep 1, 2023 |
| Barrington Research | maintain | Outperform | Jun 2, 2023 |
| Barrington Research | maintain | Outperform | May 24, 2023 |
| Barrington Research | maintain | Outperform | Mar 21, 2023 |
| Stephens & Co. | downgrade | Overweight →Equal Weight | Mar 20, 2023 |
| Barrington Research | maintain | Outperform | Mar 20, 2023 |
| Stephens & Co. | maintain | Overweight | Mar 17, 2023 |
| Barrington Research | maintain | Outperform | Oct 6, 2022 |
| Barrington Research | upgrade | Market Perform →Outperform | Aug 10, 2022 |
| Stephens & Co. | maintain | Overweight | Jul 20, 2022 |
| Barrington Research | downgrade | Outperform →Perform | Apr 6, 2022 |
| Barrington Research | downgrade | Outperform →Market Perform | Apr 5, 2022 |
| Roth Capital | maintain | Buy | Oct 3, 2021 |
| Roth Capital | maintain | Buy | Jul 29, 2021 |
Earnings History
Next report: Mar 15, 2027 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-1.08 | $-0.30 | $25.3M | $25.6M |
| Aug 5, 2026 | $-0.19 | $-0.30 | $25.3M | $25.6M |
| May 6, 2026 | $-0.43 | $-0.24 | $23.2M | $26.0M |
| Mar 9, 2026 | $-0.19 | $-0.18 | $34.2M | $35.2M |
| Nov 6, 2025 | $-0.29 | $-0.30 | $31.1M | $26.3M |
| Aug 7, 2025 | $-0.10 | $-0.09 | $36.4M | $35.4M |
| Apr 3, 2025 | $-0.47 | $-0.14 | $35.2M | $33.2M |
| Jan 2, 2025 | $-0.25 | $-0.27 | $32.6M | $29.7M |
News
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the third quarter and nine months ended September 30, 2026.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
/PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for
BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events.
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 5, 2026Insiders may stand to receive substantial financial benefi
BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MGPR NewswireNEW YORK, Oct. 3, 2026NEW YORK, Oct. 3, 2026 /PRNewswire/ --Clas
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lifecore Biomedical, Inc. (NasdaqGS: LFCR) to Webster Equity Partners. Under the terms of the proposed transaction, shareholders of Lifecore will receive $6.28 in cash for each share of Lifecore that they own. KSF is seeking to determine whether this consideration and the process that led to it.
BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)PR NewswireNEW YORK, Sept. 29, 2026NEW YORK,
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 29, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lifecore Biomedical, Inc. ("Lifecore Biomedical" or the "Company") (NASDAQ: LFCR) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Webster Equity Partners for $6.28 per share in cash at closing plus one non-tradable contingent value r…
What happened Lifecore Biomedical, Inc. (NASDAQ: LFCR) said on September 28, 2026, that it entered a definitive agreement to be acquired by Webster Equity Partners. Common stockholders will receive $6.28 per share in cash at closing, plus one non-tradable CVR per share. Series A Preferred Stockholders will receive the Conversion Amount in cash at closing,
Lifecore shareholders will receive just $6.28 per share in a transaction valued at up to $663.7 million; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Sept. 28, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Lifecore (Nasdaq: LFCR) by Webster Equity Partners, provides fair value to Lifecore's public shareholders and whether Lifecore's Board adequately protected share…
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lifecore Biomedical, Inc. (NASDAQ: LFCR) to Webster Equity Partners for $6.28 per sh
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lifecore Biomedical, Inc. (NASDAQ: LFCR) to Webster Equity Partners for $6.28 per share in cash plus one non-tradable contingent value right per share. Halper Sadeh encourages Lifecore shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investi.
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing Both Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance Milestones Stockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash an…
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference.